bims-mitran Biomed News
on Mitochondrial translation
Issue of 2026–10–04
three papers selected by
Andreas Kohler, Umeå University



  1. J Biol Chem. 2026 Sep 29. pii: S0021-9258(26)02483-X. [Epub ahead of print] 113611
      Mitochondrial DNA (mtDNA) transcription is essential for cellular energy production and is carried out by a streamlined transcription system in which transcription factor A (TFAM), transcription factor B2 (TFB2M), and the mitochondrial RNA polymerase (PolRMT) assemble at defined promoters to initiate transcription. Previous structural studies elucidated the core initiation mechanism but relied on truncated promoter templates that excluded upstream regulatory DNA interactions. Here, we present two conformations of mitochondrial transcription initiation complexes assembled on the heavy-strand promoter (HSP): a TFAM-bound complex with extended upstream DNA and a TFAM-free complex containing short linear DNA. The TFAM-bound structure reveals a transcription-stimulatory interface between PolRMT and the upstream DNA, termed upstream backbone interface (UBI), enabled by TFAM-induced promoter bending. Consistent with this structural observation, UBI truncation reduces transcription from all mtDNA promoters, an effect abolished by mutation of the PolRMT interface. In contrast, the TFAM-free structure reveals a transcription-inhibitory interaction of linear upstream DNA with the PolRMT tether helix, which would sterically clash with TFAM binding. Deletion of the tether helix increases off-target transcription, supporting an autoinhibitory role that enhances promoter specificity. Together, these findings reveal how interactions of TFAM and PolRMT with upstream DNA influence activity and specificity of mitochondrial transcription initiation.
    Keywords:  Mitochondria; PolRMT; TFAM; mitochondrial DNA (mtDNA); transcription; transcription initiation
    DOI:  https://doi.org/10.1016/j.jbc.2026.113611
  2. bioRxiv. 2026 Sep 25. pii: 2026.03.30.715437. [Epub ahead of print]
      We investigated the molecular basis of bet-hedging in budding yeast, Saccharomyces cerevisiae. Fast glycolytic growth generates two cell states: fermenting arrestors and respiring recoverers, of which only recoverers resume growth when shifted to a respiratory carbon source. Single-cell metabolic biosensors show that a bistable switch in mitochondrial activity produces these states: mitochondrial membrane potential drives import of positively charged, nuclear-encoded proteins of the mitochondrial ribosome, and mitochondrial ribosomes synthesize electron transport chain subunits that sustain the potential, completing a positive feedback loop. The ratio of mitochondrial to cytoplasmic protein synthesis governs switch dynamics: the effect of slowing mitochondrial translation is rescued by inhibiting cytosolic translation. Reducing mitochondrial translation reconstitutes bistability in evolutionarily distant fission yeast, suggesting a conserved mechanism for diversifying single-cell ATP production strategies.
    DOI:  https://doi.org/10.64898/2026.03.30.715437
  3. Life Sci Alliance. 2026 Dec;pii: e202503535. [Epub ahead of print]9(12):
      Lon protease 1 (LONP1) is a conserved hexameric protease implicated in mitochondrial disorders and cancer progression. In this study, we present PZL-26, a potent and selective small-molecule inhibitor that targets LONP1 without affecting the proteasome, leading to selective accumulation of mitochondrial proteins. Using PZL-26 in a whole-genome CRISPR-Cas9 screen, we identified genes essential for cell survival under protease inhibition, supporting a role for LONP1 in key mitochondrial processes, including complex I biogenesis, mitochondrial transcription, and translation. Our CRISPR screen results are consistent with proteomics analysis, with both approaches converging on the same mitochondrial pathways and highlighting functional interactions between LONP1 and other mitochondrial proteases, including potential compensatory mechanisms. These findings establish PZL-26 as an effective tool for exploring LONP1 function and pave the way for future therapeutic strategies targeting LONP1 in mitochondrial diseases and cancer.
    DOI:  https://doi.org/10.26508/lsa.202503535